<DOC>
	<DOCNO>NCT00918619</DOCNO>
	<brief_summary>This multi-centre , patient-blinded , intra-operatively randomise control trial . A total 126 patient plan elective liver resection enrol 9 surgical centre . The primary objective study show collagen base haemostatic device Sangustop® inferior carrier-bound fibrin sealant ( Tachosil® ) achieve haemostasis hepatic resection .</brief_summary>
	<brief_title>Efficacy Safety Sangustop® Haemostatic Agent Versus Carrier-Bound Fibrin Sealant During Liver Resection</brief_title>
	<detailed_description>During liver resection control bleed major concern . The liver predispose diffuse bleed extreme vascularity . Locally applicable agent ( haemostat ) use order achieve control parenchymatic diffuse bleed resection surface prevent intraperitoneal complication attribute bleed . These haemostat include bone wax , gelatine , collagen , oxidize regenerate cellulose , fibrin sealant glue , synthetic glue . A composite product well documented efficacy Tachosil® . It consist collagen fleece carry fibrin glue component human fibrinogen human thrombin . It show RCT superior obtain intraoperative haemostasis argon beamer liver resection . A new haemostat product Sangustop® . It indicate local haemostasis capillary bleeding bleed parenchymal organ . Sangustop® compose native absorbable collagen fibril without blood serum product pharmaceutical activity . The felt structure rich surface give framework adhesion blood platelet , thus provide additional impetus clotting . The aim study show new microfibrillar collagen hemostat Sangustop® inferior carrier-bound fibrin sealant Tachosil® regard haemostatic efficacy .</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Inclusion : Age : &gt; 18 year Gender : male / female Patients indication liver resection ( segmental nonsegmental ) Willing able complete clinical trial procedure , describe protocol Signed write informed consent participate clinical trial Exclusion : Presence sequela coagulation disorder , liver cirrhosis , Klatskin tumor Concurrent participation another clinical trial medical device medicinal product interfere endpoint Concurrent previous therapy systemic pharmacologic agent promote blood clot include limited tranexamix acid , activate factor VII , aprotinine Known allergy hypersensitivity component investigational treatment Sangustop® TachoSil® , riboflavin protein bovine origin Pregnancy breast feed Inability understand nature extent trial procedure require Missing sign write informed consent participate study Exclusion criterion check surgery ( liver resection ) : Resection area estimate operating surgeon &lt; 16cm2 Infected wind area Persistant major bleed primary haemostasis No bleeding resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>randomize ,</keyword>
	<keyword>control ,</keyword>
	<keyword>haemostatic agent ,</keyword>
	<keyword>Sangustop ,</keyword>
	<keyword>Tachosil ,</keyword>
	<keyword>liver resection ,</keyword>
	<keyword>haemostasis</keyword>
</DOC>